EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Do Serologic Domains of the 2023 ACR/EULAR Classification Criteria for Antiphospholipid Syndrome Define Distinct Clinical Subgroups During Pregnancy?

Sara Del Barrio-Longarela iD, José L Hernández iD, Ana Merino, Leyre Riancho-Zarrabeitia, Alejandra Comins-Boo, Marcos López-Hoyos iD, Rafael Gálvez-Sánchez iD, Víctor M Martínez-Taboada iD

International Journal of Molecular Sciences · 08.07.2026 · 27 (14) · 6100

DOI: 10.3390/ijms27146100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.07.2026. Verfasst von Sara Del Barrio-Longarela und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Obstetrics and Gynecology, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, Pregnancy Complications, Antibodies, Antiphospholipid. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To evaluate the clinical applicability of the 2023 ACR/EULAR serologic classification criteria for antiphospholipid syndrome (APS) in a cohort of pregnant women across the APS spectrum, and to assess the association between serologic burden and clinical manifestations, obstetric outcomes, and treatment response, a retrospective cohort study was conducted including 190 pregnant women with persistent antiphospholipid antibody (aPL) positivity. Patients were classified according to the ACR/EULAR serologic criteria into two groups: high serologic burden (≥3 points) and low serologic burden (≤2 points). Clinical, obstetric, therapeutic, and reproductive variables were compared between groups. Nearly one-third of women did not meet the 2023 ACR/EULAR serologic threshold. Although most patients with thrombotic or obstetric APS fulfilled the ACR/EULAR serologic threshold, 28% of women with obstetric APS and 35.3% of those with pregnancy-related morbidity had ≤2 serologic points. Baseline demographic characteristics were similar between groups. Obesity (23.9% vs. 10%; p = 0.04) and obstetric comorbidity (17.9% vs. 5.4%; p = 0.02) were more frequent among patients with higher serologic burden. Rates of obstetric complications were comparable between groups. The most commonly prescribed treatment was low-dose aspirin combined with low-molecular-weight heparin, with no differences according to serologic classification. Live birth rates and adverse pregnancy outcomes were comparable between groups, with favorable outcomes observed in treated pregnancies. Serologic burden as defined by the 2023 ACR/EULAR criteria does not reliably predict obstetric complications, nor identify a clinically more severe subgroup. These findings highlight that clinical judgment beyond formal classification frameworks remains essential when managing pregnant women with antiphospholipid antibodies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiphospholipid SyndromePregnancy ComplicationsAntibodies, AntiphospholipidHumansFemalePregnancyAdultRetrospective StudiesPregnancy Outcome

Stichwörter der Autor:innen

ACR/EULAR criteriaantiphospholipid antibodiesantiphospholipid syndromeautoimmunityclassification criteriapregnancy morbidityserologic burden

Substanzen

Antibodies, Antiphospholipid

Autor:innen und Institutionen

  • Division of Obstetrics and Gynecology, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.
  • Department of Internal Medicine, Hospital Universitario Marqués de Valdecilla-IDIVAL (Instituto de Investigación Valdecilla), 39008 Santander, Spain.
  • Departamento de Medicina y Psiquiatría, Universidad de Cantabria, 39008 Santander, Spain.
  • Rheumatology Department, Hospital Sierrallana-IDIVAL (Instituto de Investigación Valdecilla), 39300 Torrelavega, Spain.
  • Immunology Department, Hospital Universitario Marqués de Valdecilla-IDIVAL (Instituto de Investigación Valdecilla), 39011 Santander, Spain.
  • Departamento de Biología Molecular, Universidad de Cantabria, 39011 Santander, Spain.

ORCID-Profile: Sara Del Barrio-Longarela, José L Hernández, Marcos López-Hoyos, Rafael Gálvez-Sánchez, Víctor M Martínez-Taboada

Zitieren

APA

Del Barrio-Longarela, S., Hernández, J. L., Merino, A., Riancho-Zarrabeitia, L., Comins-Boo, A., López-Hoyos, M., Gálvez-Sánchez, R., & Martínez-Taboada, V. M. (2026). Do Serologic Domains of the 2023 ACR/EULAR Classification Criteria for Antiphospholipid Syndrome Define Distinct Clinical Subgroups During Pregnancy?. International Journal of Molecular Sciences, 27(14), 6100. https://doi.org/10.3390/ijms27146100

Vancouver

Del Barrio-Longarela S, Hernández JL, Merino A, Riancho-Zarrabeitia L, Comins-Boo A, López-Hoyos M, et al. Do Serologic Domains of the 2023 ACR/EULAR Classification Criteria for Antiphospholipid Syndrome Define Distinct Clinical Subgroups During Pregnancy?. International Journal of Molecular Sciences. 2026;27(14):6100. doi:10.3390/ijms27146100

BibTeX
@article{DelBarrioLongarela2026,
  author = {Del Barrio-Longarela, Sara and Hernández, José L and Merino, Ana and Riancho-Zarrabeitia, Leyre and Comins-Boo, Alejandra and López-Hoyos, Marcos and Gálvez-Sánchez, Rafael and Martínez-Taboada, Víctor M},
  title = {Do Serologic Domains of the 2023 ACR/EULAR Classification Criteria for Antiphospholipid Syndrome Define Distinct Clinical Subgroups During Pregnancy?},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {14},
  pages = {6100},
  doi = {10.3390/ijms27146100}
}
Kostenlos starten →